Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21946383 | 0.82 | NPSR1 (0.35) | NPSR1LMNAKMT2A | |
| SCHEMBL14888179 | 0.82 | NCF1 (0.39) | NPSR1 | |
| Hydrochloric Acid SCHEMBL14311891 | 0.80 | NCF1 (0.38) | NPSR1 | |
| SCHEMBL14431986 | 0.78 | — | — | |
| SCHEMBL23081050 | 0.75 | CYP2D6 (0.30) | — | |
| SCHEMBL23081047 | 0.75 | CYP2D6 (0.30) | — | |
| SCHEMBL17248104 | 0.73 | EPHX2 (0.37) | NPSR1 | |
| SCHEMBL21216554 | 0.72 | NPSR1 (0.43) | NPSR1LMNAKMT2A | |
| SCHEMBL25082216 | 0.71 | KMT2A (0.36) | KMT2A | |
| SCHEMBL19014426 | 0.71 | OPRM1 (0.37) | LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023227698-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2023-11-30 | — | — | WO | disclosed |
| US-10918622-B2 | Compounds useful as kinase inhibitors | LOXO ONCOLOGY, INC. (US) | 2021-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10918622-B2 | Compounds useful as kinase inhibitors | BTK, ABL1, LCK | NPSR1 4425/4885LMNA 4225/4885KMT2A 688/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.